The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Rational design of shepherdin, a novel anticancer agent
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70
Sawada, M., Hayes, P., & Matsuyama, S. (2003) · Nature Cell Biology · doi:10.1038/ncb955 · Cited by 161
RetractedEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“…which indistinguishably affected tumor cell types of different derivations, regardless of their proliferative condition (Swanton, 2004), p53 status (Vogelstein et al., 2000), or overexpression of potent survival signals, e.g., Bcl-2 (Johnstone et al., 2002), all conditions that typically…”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Control of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,870
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Validating survivin as a cancer therapeutic target
Altieri, D. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc968 · Cited by 1,206
Self-citationPathways of apoptotic and non-apoptotic death in tumour cells
Okada, H., & Mak, T. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1412 · Cited by 1,044
Young, J. C., Moarefi, I., & Hartl, F. U. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200104079 · Cited by 822
Structural basis for phosphoserine-proline recognition by group IV WW domains.
Verdecia, M. A., Bowman, M. E., Lu, K. P., Hunter, T. R., & Noel, J. P. (2000) · Nature Structural Biology · doi:10.1038/77929 · Cited by 704
`The stress of dying': the role of heat shock proteins in the regulation of apoptosis
Beere, H. M. (2004) · Journal of Cell Science · doi:10.1242/jcs.01284 · Cited by 639
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Functional requirement of p23 and Hsp90 in telomerase complexes
Holt, S. E., Aisner, D. L., Baur, J., Tesmer, V. M., Dy, M., Ouellette, M., Trager, J. B., Morin, G. B., Toft, D. O., Shay, J. W., et al. (1999) · Genes & Development · doi:10.1101/gad.13.7.817 · Cited by 539
Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M., & Neckers, L. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003701200 · Cited by 502
Meyer, P., Prodromou, C., Hu, B., Vaughan, C., Roe, S. M., Panaretou, B., Piper, P. W., & Pearl, L. H. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00065-0 · Cited by 491
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis
Dohi, T., Beltrami, E., Wall, N. R., Plescia, J., & Altieri, D. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422222 · Cited by 405
Self-citationNeckers, L., & Ivy, S. P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00003 · Cited by 400
The Mechanism of Hsp90 Regulation by the Protein Kinase-Specific Cochaperone p50cdc37
Roe, S. M., Ali, M. M. U., Meyer, P., Vaughan, C. K., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2004) · Cell · doi:10.1016/s0092-8674(03)01027-4 · Cited by 349
Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement.
Noel, J. P., Verdecia, M. A., Huang, H.-K., Sonnenburg, E. D., Kaiser, D. A., & Hunter, T. R. (2000) · Nature Structural Biology · doi:10.1038/76838 · Cited by 337
Genomic instability — the engine of tumorigenesis?
Sieber, O. M., Heinimann, K., & Tomlinson, I. P. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1170 · Cited by 324
Regulation of survivin function by Hsp90
Fortugno, P., Beltrami, E., Plescia, J., Fontana, J., Pradhan, D., Marchisio, P. C., Sessa, W. C., & Altieri, D. C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434345100 · Cited by 318
Self-citationSelective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4325 · Cited by 314
Hong, S. Y., Oh, J. E., & Lee, K.-H. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00259-2 · Cited by 274
Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Swanton, C. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01321-4 · Cited by 248
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Sausville, E., Tomaszewski, J., & Ivy, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481831 · Cited by 225
Morishima, Y., Murphy, P. J. M., Li, D.-P., Sanchez, E. R., & Pratt, W. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000434200 · Cited by 166 · cited 3×
“458 cellular context, we reconstituted this interaction in reticulocyte extracts, which have been used before to assemble functional Hsp90 complexes (Morishima et al., 2000).”
MethodInfluentialCrystal Structure and Mutagenic Analysis of the Inhibitor-of-Apoptosis Protein Survivin
Muchmore, S. W., Chen, J., Jakob, C. G., Zakula, D., Matayoshi, E. D., Wu, W., Zhang, H., Li, F., Ng, S., & Altieri, D. C. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00018-6 · Cited by 132
Self-citationBrugidou, J., Legrand, C., Méry, J., & Rabié, A. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2340 · Cited by 106
Fukuda, S., Mantel, C., & Pelus, L. M. (2003) · Blood · doi:10.1182/blood-2003-05-1756 · Cited by 94
Full-length dominant-negative survivin for cancer immunotherapy.
Писарев, В. М., Yu, B., Salup, R. R., Sherman, S., Altieri, D. C., & Gabrilovich, D. I. (2003) · PubMed · Cited by 93
Self-citationNovel Approaches for Targeted Cancer Therapy
Guillemard, V., & Saragovi, H. U. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043332989 · Cited by 81
O'Dwyer, M. E., & Druker, B. J. (2000) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00149-2 · Cited by 75
Hervé, M., Maillére, B., Mourier, G., Texier, C., Leroy, S., & Ménez, A. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00004-7 · Cited by 48
Pescarolo, M. P., Bagnasco, L., Malacarne, D., Melchiori, A., Valente, P., Millo, E., Bruno, S., Basso, S., & Parodi, S. (2000) · The FASEB Journal · doi:10.1096/fj.00-0422fje · Cited by 46
Lee, Y. S., Marcu, M. G., & Neckers, L. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.05.010 · Cited by 35
(1998) · doi:10.1002/(sici)1096-987x(19981115)19:14<1639::aid-jcc10>3.0.co;2-b
Cited by
Targeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Self-citationApoptosis and cancer: mutations within caspase genes
Ghavami, S., Hashemi, M., Ande, S. R., Yeganeh, B., Xiao, W., Eshraghi, M., Bus, C. J., Kadkhoda, K., Wiechec, E., Halayko, A. J., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066944 · Cited by 713
IAP-targeted therapies for cancer
LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., & Korneluk, R. G. (2008) · Oncogene · doi:10.1038/onc.2008.302 · Cited by 524
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
Metadata
- Authors
- Plescia, J., Salz, W., Xia, F., Pennati, M., Zaffaroni, N., Daidone, M. G., Meli, M., Dohi, T., Fortugno, P., Nefedova, Y., Gabrilovich, D. I., Colombo, G., & Altieri, D. C.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 7
- Issue
- 5
- Pages
- 457-468
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2096088010
- Cited by
- 341
- References
- 40
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.